Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07533019 | A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo | PHASE2 | RECRUITING | 60 | — | — | Apr 14, 2026 | Sep 1, 2027 | Jun 4, 2026 | 35 | United States, Belgium +3 |
| Arm | Type | Description |
|---|---|---|
| LY4005130 | EXPERIMENTAL | LY4005130 administered intravenously (IV) |
| Placebo | PLACEBO_COMPARATOR | Placebo administered IV |
| Name | Type | Description |
|---|---|---|
| LY4005130 | DRUG | Administered IV |
| Placebo | DRUG | Administered IV |
Inclusion Criteria: * Eligible participants must have the following at both screening and baseline: * A clinical diagnosis of non-segmented vitiligo (NSV) for at least 3 months * Body surface area (BSA) involvement of 4% to 60%, inclusive, excluding involvement at palms of the hands, soles of ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Incyte Corporation | INCY | 5 | PHASE3 | Povorcitinib, Ruxolitinib, Vehicle |
| Pfizer Inc. | PFE | 2 | PHASE3 | Ritlecitinib |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Upadacitinib |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Zasocitinib |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | GIA632 |
| Arcutis Biotherapeutics Inc | ARQT | 1 | PHASE2 | Roflumilast 0.3% foam |
| Forte Biosciences Inc. | FBRX | 1 | PHASE1 | FB102 |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 1 | PHASE1 | TEV-53408 |